Yahoo Finance • last month
LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • 2 months ago
Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund (XLV) 0 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, Wednesday announced that the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dyst... Full story
Yahoo Finance • 2 months ago
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story
Yahoo Finance • 2 months ago
Investing.com - H.C. Wainwright lowered its price target on Keros Therapeutics (NASDAQ:KROS) to $20.00 from $25.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock appears undervalued at cur... Full story
Yahoo Finance • 2 months ago
Investing.com - Keros (NASDAQ: KROS) reported second quarter EPS of $-0.76, $0.37 better than the analyst estimate of $-1.13. Revenue for the quarter came in at $18.17M versus the consensus estimate of $4.21M. Keros’s stock price closed a... Full story
Yahoo Finance • 2 months ago
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ker... Full story
Yahoo Finance • 2 months ago
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • 4 months ago
LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • 4 months ago
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story
Yahoo Finance • 4 months ago
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024... Full story
Yahoo Finance • 4 months ago
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company”... Full story
Yahoo Finance • 5 months ago
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Ur... Full story
Yahoo Finance • 5 months ago
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,... Full story
Yahoo Finance • 5 months ago
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wid... Full story
Yahoo Finance • 6 months ago
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical... Full story
Yahoo Finance • 6 months ago
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular... Full story
Yahoo Finance • 9 months ago
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS) on... Full story
Yahoo Finance • 2 years ago
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story